Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by bionicjoeon Mar 06, 2019 10:13am
71 Views
Post# 29448984

RE:RE:Volume versus increase in share price - "don't like it"

RE:RE:Volume versus increase in share price - "don't like it"
floatinketucky wrote: ISSUER: Theralase Technologies Inc. Principal Jurisdiction - Ontario
DATES: Preliminary Shelf Prospectus (NI 44-102) dated July 30, 2018 Closed on December 18, 2018
PROJECT NUMBER: 2800145 

TLT is unable to do a PP the the procpectus closed. Do you agree?

SouthernTierTom How does this fit into your ideal?

"A LOT of people are cashing in their shares at this level I STILL maintain there will be a cheaper financing that will benefit those getting out at this level that are "privileged" to get PP paper with warrants. Way too bullboard program from our pals. "





They wouldn't do a PP under the shelf prospectus plan but why couldn't they do a regular PP which is structured a little differently or for that matter a brokered deal which has the same dilutive effect for shareholders?

Isn't it unusual to have the OSC make the shelf prospectus termination disclosure with no word from TLT as to the reason why such action was taken? One would think they could have kept the shelf prospectus in place and still seek a JV with a strategic partner. I don't see how the two would conflict.

Bullboard Posts